Group 1: Company Overview and Strategic Decisions - The company, Zhejiang Weikang Pharmaceutical Co., Ltd., focuses on modern Chinese medicine and Western medicine research, production, and sales [2] - The decision to sell Zhejiang Weikang Pharmaceutical Retail Co., Ltd. and Zhejiang Weikang Pharmacy Co., Ltd. aims to concentrate resources on pharmaceutical manufacturing [2] Group 2: Research and Development (R&D) Efforts - The company has established a comprehensive new drug R&D system, including market research and strict control at various stages of development [3] - As of the end of 2024, the company holds 37 drug approval numbers, with key products like Yinhuang Diban and Roxithromycin Soft Capsules having patents and core technologies [3] Group 3: Shareholder Returns - For the fiscal year 2024, the company plans to distribute a cash dividend of 1.4 yuan (after tax) for every 10 shares [3] - The company has a shareholder return plan for 2025-2027, committing to distribute at least 20% of the annual distributable profits in cash [3] Group 4: Future R&D Directions - The company will continue to develop innovative traditional Chinese medicine products and improve existing key products [4][5] - There is a focus on developing short-term projects with good market prospects, low investment, and shorter R&D cycles [5] Group 5: Industry Outlook - The company is optimistic about the future of the traditional Chinese medicine industry, supported by rising income levels, an aging population, and enhanced health awareness [5] - National policies are increasingly favoring the innovation and development of traditional Chinese medicine, contributing to the industry's vitality [5]